RNLC2131

Brief Summary

The primary objective of this study is to assess the efficacy of Rifaximin SSD versus placebo in preventing initial complications of liver cirrhosis and all-cause mortality in subjects with liver cirrhosis.

The secondary objectives of this study in subjects with compensated liver cirrhosis are to:

• Assess the safety of Rifaximin SSD following a 24-week treatment regimen

• Assess the population pharmacokinetics of Rifaximin SSD

• Characterize the gastrointestinal microbiota from stool samples, and antibiotic resistance from bacteria cultured from stool samples before and after treatment with Rifaximin SSD

• Assess the effects of treatment with Rifaximin SSD on biological markers of liver cirrhosis

• Assess the effects of treatment with Rifaximin SSD on liver-cirrhosis-related infections